Advances in the medical treatment of rheumatoid arthritis

Hand Clinics

Volumn 27, Issue 1, 2011, Pages 11-20

  Kahlenberg, J Michelle ^a   Fox, David A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biologic therapy; Disease modifying antirheumatic drugs; Perioperative management; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ETANERCEPT; GOLIMUMAB; HYDROCORTISONE; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADJUVANT THERAPY; BACTERIAL INFECTION; BONE EROSION; CANCER RISK; CARDIOVASCULAR DISEASE; CARTILAGE DEGENERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFECTION RISK; INJECTION SITE REACTION; INTESTINE PERFORATION; JOINT DESTRUCTION; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LUNG TOXICITY; LYMPHOMA; NAUSEA; NEUTROPENIA; PERIOPERATIVE PERIOD; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINA DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOFT TISSUE INFECTION; SYNOVITIS; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 78650243017     PISSN: 07490712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hcl.2010.09.002     Document Type: Review

References (50)

1. Vosse D., de Vlam K. Osteoporosis in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009, 27:S62.
2. Gravallese E., Harada Y., Wang J., et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943.
3. Walsh N.C., Reinwald S., Manning C.A., et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009, 24:1572.
4. Ideguchi H., Ohno S., Hattori H., et al. Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther 2006, 8:R76.
5. Sinigaglia L., Nervetti A., Mela Q., et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian study group on bone mass in rheumatoid arthritis. J Rheumatol 2000, 27:2582.
6. El Maghraoui A., Rezqi A., Mounach A., et al. Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment. Rheumatology 2010, 49(7):1303-1310.
7. Matos M., Tannuri U., Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol 2010, 11:7.
8. Devouassoux G., Cottin V., Liote H., et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009, 33:1053.
9. Kelly C., Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother 2008, 9:3221.
10. Mori S., Cho I., Koga Y., et al. A simultaneous onset of organizing pneumonia and rheumatoid arthritis, along with a review of the literature. Mod Rheumatol 2008, 18:60.
11. Radovits B.J., Fransen J., Shamma S.A., et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 2010, 62:362.
12. Peters M.J.L., VPv Halm, Voskuyl A.E., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Care Res 2009, 61:1571.
13. Bergholm R., Leirisalo-Repo M., Vehkavaara S., et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 22:1637.
14. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722.
15. Verstappen S.M.M., Jacobs J.W.G., Bijlsma J.W.J., et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003, 48:1797.
16. Weng H.H., Ranganath V.K., Khanna D., et al. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis. J Rheumatol 2010, 37:550.
17. Ma M.H.Y., Kingsley G.H., Scott D.L. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 2010, 49:91.
18. Chan E.S.L., Cronstein B. Methotrexate-how does it really work?. Nat Rev Rheumatol 2010, 6:175.
19. Furst D.E., Breedveld F.C., Kalden J.R., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010, 69(Suppl 1):i2-29.
20. Pincus T., Ferraccioli G., Sokka T., et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 2002, 41:1346.
21. Strand V., Cohen S., Schiff M., et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999, 159:2542.
22. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577.
23. Wasko M.C.M., Hubert H., Lingala V., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007, 298:187.
24. Tam L.S., Gladman D.D., Hallett D.C., et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000, 27:2142.
25. Hannonen P., Möttönen T., Hakola M., et al. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993, 36:1501.
26. Statkute L., Ruderman E.M. Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2010, 19:105.
27. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26.
28. Genovese M.C., Schiff M., Luggen M., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:547.
29. Marston B., Palanichamy A., Anolik J.H. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010, 22:307.
30. Keystone E., Emery P., Peterfy C.G., et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009, 68:216.
31. Mease P.J., Cohen S., Gaylis N.B., et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010, 37.
32. Kremer J.M., Genant H.K., Moreland L.W., et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008, 58:953.
33. Simon T., Askling J., Lacaille D., et al. Infections requiring hospitalization in the Abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther 2010, 12:R67.
34. Mertens M., Singh J.A. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009, 1. CD005121.
35. Emery P., Keystone E., Tony H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516.
36. Oldfield V., Dhillon S., Plosker G.L. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009, 69:609.
37. Mushtaq S., Goodman S.M., Scanzello C.R. Perioperative management of biologic agents used in treatment of rheumatoid arthritis. Am J Ther 2010, [online].
38. Curtis J.R., Patkar N., Xie A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56:1125.
39. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522.
40. Kim S.Y., Solomon D.H. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010, 6:165.
41. Roux C.H., Brocq O., Breuil V., et al. Safety of anti-TNF-{alpha} therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006, 45:1294.
42. Fleischmann R.M. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009, 60:3225.
43. Askling J.A., Bongartz T.B. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:334.
44. Strangfeld A., Hierse F., Rau R., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010, 12:R5.
45. Mariette X., Tubach F., Bagheri H., et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69:400.
46. Neva M.H., Häkkinen A., Mäkinen H., et al. High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery. Ann Rheum Dis 2006, 65:884.
47. Coursin D.B., Wood K.E. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002, 287:236.
48. Fleager K., Yao J. Perioperative steroid dosing in patients receiving chronic oral steroids, undergoing outpatient hand surgery. J Hand Surg 2010, 35:316.
49. Bongartz T., Halligan C.S., Osmon D.R., et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Care Res 2008, 59:1713.
50. Pieringer H., Stuby U., Biesenbach G. The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008, 27:1217.